Department of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou 215228, China.
Central Laboratory, First Affiliated Hospital, Institute (College) of Integrative Medicine, Dalian Medical University, Dalian 116021, China.
Aging (Albany NY). 2024 Jan 29;16(3):2232-2248. doi: 10.18632/aging.205479.
Immune-related enhancer RNAs (eRNAs) have garnered significant attention in cancer metabolism research, yet their specific roles in ccRCC have remained elusive.
We retrieved eRNA expression profiles from TCGA database and identified immune-related eRNAs (IREs) by assessing their co-expression with immune genes. Utilizing consensus clustering, we organized these IREs into two distinct clusters. The construction of an IREs signature was accomplished through the LASSO and multivariate Cox analysis. Furthermore, we performed Cell Counting Kit-8 and clonogenic assays to assess changes in the proliferative capacity of Caki-1 and 769-P cells.
The existence of two clusters of immune-related eRNAs in ccRCC, each with distinctive prognostic and immunological attributes. Cluster B exhibited immunosuppressive properties and displayed a positive correlation with immunosuppressive cells. Functional enrichment analysis unveiled their involvement in several tumor-promoting pathways, metabolic pathways and immune pathways. The IREs signature demonstrated its potential to accurately predict patient immune and prognostic characteristics. AC003092.1, an eRNA strongly associated with patient survival, emerged as a potential oncogene significantly linked to adverse prognosis and the presence of immunosuppressive cells and checkpoints in ccRCC patients. Notably, AC003092.1 displayed marked upregulation in ccRCC tissues and cell lines, and its knockdown substantially inhibited the proliferation of Caki-1 and 769-P cells.
We established a robust predictive model that played a vital role in determining the prognosis, clinicopathological characteristics and immune cell infiltration patterns of ccRCC patients. IRE, particularly AC003092.1, which was strongly associated with survival, hold promise as novel immunotherapeutic targets for ccRCC.
免疫相关增强子 RNA(eRNA)在癌症代谢研究中受到了广泛关注,但它们在 ccRCC 中的具体作用仍不清楚。
我们从 TCGA 数据库中检索了 eRNA 表达谱,并通过评估它们与免疫基因的共表达来鉴定免疫相关 eRNA(IRE)。利用共识聚类,我们将这些 IRE 分为两个不同的簇。通过 LASSO 和多变量 Cox 分析构建 IRE 特征。此外,我们还进行了细胞计数试剂盒-8 和集落形成实验,以评估 Caki-1 和 769-P 细胞增殖能力的变化。
ccRCC 中存在两种免疫相关 eRNA 簇,每个簇都具有独特的预后和免疫学特征。簇 B 表现出免疫抑制特性,与免疫抑制细胞呈正相关。功能富集分析显示它们参与了几个促进肿瘤的途径、代谢途径和免疫途径。IRE 特征显示出准确预测患者免疫和预后特征的潜力。与患者生存密切相关的 eRNA AC003092.1 是一个潜在的致癌基因,与 ccRCC 患者的不良预后、免疫抑制细胞和检查点的存在显著相关。值得注意的是,AC003092.1 在 ccRCC 组织和细胞系中显著上调,其敲低显著抑制了 Caki-1 和 769-P 细胞的增殖。
我们建立了一个强大的预测模型,对确定 ccRCC 患者的预后、临床病理特征和免疫细胞浸润模式起着至关重要的作用。IRE,特别是与生存密切相关的 AC003092.1,有望成为 ccRCC 的新型免疫治疗靶点。